News for Immunome, Inc. (IMNM)

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that t

[url="]Immunome,[/url] Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today ann

On December 31, 2024, Redmile Group, LLC (Trades, Portfolio) executed a significant transaction involving Zymeworks Inc (ZYME), reducing its holdings by 261,448

On December 31, 2024, Redmile Group, LLC (Trades, Portfolio) made a notable acquisition by purchasing 7,197,951 shares of Silence Therapeutics PLC. This transac

Recent Transaction Overview On December 31, 2024, Janus Henderson Group PLC executed a strategic transaction involving Immunome Inc (IMNM). The firm reduced its

Immunome, Inc. (the ”œCompany”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, an

Colorado-based Aclarion, Inc. (ACON) is up over 30 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Colorado-based Aclarion, Inc. (ACON) is up over 30 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Immunome, Inc. (”œImmunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today

Immunome's varegacestat is in a phase 3 trial in patients with desmoid tumors that should produce results in H2'25. Read why I remain bullish on IMNM stock.

Immunome (IMNM) announces pricing of underwritten public offering of common stock, expected to raise $150 million before expenses.

Hummingbird Bioscience grants Immunome exclusive license to monoclonal antibodies for undisclosed target, receiving upfront payment and royalties.

SAN FRANCISCO and SINGAPORE, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transfor

Immunome, Inc. (the ”œCompany”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, an

Stocks Analysis by MarketBeat.com (Nathan Reiff) covering: NVIDIA Corporation, Hallador Energy Company, Immunome Inc, Alliance Entertainment Holding Corp. Read MarketBeat.com (Nathan Reiff)'s latest article on Investing.com

Immunome has a turbulent history, shifting focus from COVID-19 therapies to oncology. Read what the future may hold for this small-cap biotech.

$426.4M cash, cash equivalents and marketable securities as of June 30, 2024;Projected cash runway into mid-2026 SAN DIEGO, Aug. 09, 2024...

Immunome Announces Completion of Purchase of Assets from Atreca

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update